Rapid Evaluation and Treatment of Suspected Congenital CMV
For an infant with suspected congenital CMV, immediately obtain urine CMV PCR testing within the first 3 weeks of life (ideally within 2 weeks) to confirm diagnosis, as this is the only window for definitively establishing congenital infection, and initiate comprehensive evaluation for symptomatic disease to determine treatment eligibility.
Diagnostic Approach
Timing is Critical
- Urine CMV PCR or viral culture must be obtained within 21 days of birth to distinguish congenital from postnatal infection 1
- Testing after 3 weeks cannot definitively establish congenital infection
- Saliva PCR can be used for initial screening but requires urine confirmation due to potential contamination
Who to Test
Test infants with:
- Failed newborn hearing screen (only 57% of infants with cCMV who develop hearing loss will refer on initial screening) 2
- Physical examination findings:
- Microcephaly (head circumference <10th percentile)
- Petechiae or purpura
- Hepatosplenomegaly
- Jaundice
- Seizures
- Laboratory abnormalities: thrombocytopenia, elevated transaminases
- Intrauterine growth restriction (IUGR) or small for gestational age (SGA) only if accompanied by physical signs or additional risk factors 3
- Abnormal neuroimaging findings
Common Pitfall: Avoid testing isolated IUGR/SGA without other findings—this has extremely low diagnostic yield and wastes resources 3
Evaluation of Confirmed cCMV
Once diagnosis is confirmed, rapidly determine if the infant is symptomatic or asymptomatic, as this dictates treatment:
Symptomatic Disease Evaluation
Obtain within 48-72 hours:
- Complete blood count with differential (thrombocytopenia, neutropenia)
- Comprehensive metabolic panel (transaminitis)
- Head ultrasound or brain MRI (intracranial calcifications, neuronal migration defects, ventriculomegaly)
- Ophthalmologic examination (chorioretinitis)
- Auditory brainstem response (ABR) testing
- Quantitative CMV PCR from blood/plasma (viral load)
Classification
- Symptomatic: Any CNS involvement (abnormal neuroimaging, microcephaly), end-organ disease (hepatosplenomegaly, thrombocytopenia, petechiae, elevated transaminases), or chorioretinitis
- Asymptomatic: Normal physical examination and laboratory/imaging studies
Treatment Decision Algorithm
Symptomatic Infants
Treat with antiviral therapy 4, 5:
- Valganciclovir 16 mg/kg/dose PO twice daily for 6 months
- Alternative: IV ganciclovir 6 mg/kg/dose every 12 hours (if unable to tolerate oral)
- Treatment improves hearing outcomes and neurodevelopmental outcomes 5
- Monitor CBC weekly for first month, then every 2 weeks (neutropenia risk)
Asymptomatic Infants
- No antiviral therapy indicated based on current evidence
- However, these infants remain at risk: 20-25% will develop late-onset or progressive hearing loss 2
- Critical: Establish rigorous audiologic surveillance (see below)
Extremely Preterm Infants
- Treatment is feasible and appears safe with careful monitoring 6
- Consider treatment for symptomatic disease even in extreme prematurity
- Requires close hematologic monitoring but toxicity appears manageable
Long-Term Monitoring
All Infants with cCMV (Symptomatic and Asymptomatic)
Audiologic surveillance is mandatory 2:
- ABR at diagnosis
- Repeat hearing assessment at 3,6,9,12,18, and 24 months
- Annual audiometry through age 6 years minimum
- Hearing loss can be late-onset (up to 18 years) and progressive 2
- Rapid deterioration can occur: 11.3% of asymptomatic infants develop hearing loss by 12 months 2
Additional Monitoring
- Neurodevelopmental assessment at 6,12,18,24 months and annually
- Ophthalmologic follow-up every 6 months for first 2 years
- Monitor for vestibular and balance disorders (emerging concern in up to 50% of asymptomatic cases) 2
Key Clinical Pearls
The 10-85-20 Rule 2:
- 10-15% of cCMV infants are symptomatic at birth (>50% develop long-term disabilities)
- 85-90% are asymptomatic at birth
- 20% of asymptomatic infants will develop hearing loss in childhood
Incidence: 1 in 200 live births in the US, making it more common than many conditions on routine newborn screening panels 2
Health Disparities: Higher rates in lower-income and marginalized racial/ethnic groups 2